Protein MRI contrast agent with unprecedented metal selectivity and sensitivity for liver cancer imaging
- 13 May 2015
- journal article
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 112 (21) , 6607-6612
Abstract
Significance: Primary and metastatic liver cancers that are associated with high mortality rates and poor treatment responses are only diagnosed at late stages, due to the lack of highly sensitive contrast agents and robust imaging methodologies. We have developed a protein MRI contrast agent (ProCA32) by engineering high-affinity Gd 3+ -binding pockets in rat and human α-parvalbumin. ProCA32 can function as both a T 1 - and T 2 -weighted contrast agent, which enables noninvasive detection of early-stage micrometastatic liver tumors with sizes as small as 0.24 mm using T 1 - and T 2 -weighted or T 2 /T 1 ratio MRI. Our protein-based MRI contrast agents and imaging methodology are expected to provide robust results for the early detection of liver cancer as well as other liver diseases.Keywords
Funding Information
- HHS | National Institutes of Health (EB007268, GM62999, CA118113)
- HHS | National Institutes of Health (CA176001, P30EY06360)
- HHS | National Institutes of Health (S10RR023706)
This publication has 33 references indexed in Scilit:
- Quantitative multimodality imaging in cancer research and therapyNature Reviews Clinical Oncology, 2014
- A reference agent model for DCE MRI can be used to quantify the relative vascular permeability of two MRI contrast agentsMagnetic Resonance Imaging, 2013
- Progression of Ocular Melanoma Metastasis to the LiverJAMA Ophthalmology, 2013
- The Multifaceted Role of the Microenvironment in Liver Metastasis: Biology and Clinical ImplicationsCancer Research, 2013
- Pathogenic mechanisms in HBV- and HCV-associated hepatocellular carcinomaNature Reviews Cancer, 2013
- Strategies for the discovery and development of therapies for metastatic breast cancerNature Reviews Drug Discovery, 2012
- Locoregional Management of Hepatic Metastasis From Primary Uveal MelanomaSeminars in Oncology, 2010
- Bioresponsive, Cell-Penetrating, and Multimeric MR Contrast AgentsAccounts of Chemical Research, 2009
- Rational Design of Protein-Based MRI Contrast AgentsJournal of the American Chemical Society, 2008
- Tissue-specific MR contrast agentsEuropean Journal of Radiology, 2003